Speaker illustration

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

What's the next STEP in HFpEF?

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Glucagon-like peptide 1 receptor agonists in clinical cardiology practice

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Consequences of COVID-19 in heart failure: one year on

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Abstract Sessions

Thumbnail

6 years on, what have we learned from Real World use of PCSK9i?

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Event: ESC CONGRESS 2019

Topic: Cardiovascular Disease in Special Populations

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Diabetes and the heart

Event: ESC CONGRESS 2019

Topic: Diabetes and the Heart

Session type: Moderated Posters

Thumbnail

New frontiers: SGLT2 inhibitors in cardiorenal disease

Event: ESC CONGRESS 2019

Topic: Antidiabetic Pharmacotherapy

Session type: Advances in Science

Thumbnail

Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)

Event: ESC CONGRESS 2017

Topic: Heart failure, other

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

This platform is supported by

logo Novo Nordisk